Neena Brizmohun
Deputy Editor
Deputy Editor
UK
35+ years of experience
Neena's other specialist areas include new medicines coming to market in the EU, clinical trials, post-marketing safety monitoring, transparency policies relating to the publication of trial data, and global harmonization initiatives for pharma and medtech.
A scientist by training, Neena started her journalistic career at Informa in 1997. Before becoming a journalist she worked as a biomedical scientist at St Thomas' Hospital in London for 10 years.
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース
By Neena Brizmohun 27 Nov 2020
With Novartis’s and Kite’s CAR T-cell therapies both expected to gain recommendations for pan-EU approval this week, discounts will need to be negotiated for these new treatments to reach the markets in Europe.
Topic Cell & Gene Therapy
世界の薬事規制動向＆情報を配信
By Neena Brizmohun 23 Nov 2020
Joining the international regulatory collaboration could become a key route for the UK to remain an early and priority market for global launches after the end of the Brexit transition period, says the industry group, BIA.
Topic Pharma-Brexit Brexit
世界の薬事規制動向＆情報を配信
By Neena Brizmohun 28 Aug 2020
The former industry executive and incoming MHRA chair says he wants to see the agency become an “enabler” in the UK health system. Meanwhile, the MHRA is still looking for a permanent chief executive after Ian Hudson stepped down from the post nearly a year ago.
Topic Regulation BioPharmaceutical
世界の薬事規制動向＆情報を配信
By Neena Brizmohun 07 Apr 2020
Recommendations from the European Medicines Agency explain the conditions under which early access to remdesivir could be given through compassionate use programs.
Topic Coronavirus
世界の薬事規制動向＆情報を配信
By Neena Brizmohun 02 Apr 2020
The regulatory agency also urges qualified persons at drug companies to let the agency know as soon as possible if they are finding that the new measures are not flexible enough to deal with the current logistical challenges quickly.
Topic Coronavirus Distribution
世界の薬事規制動向＆情報を配信
By Neena Brizmohun 09 Aug 2019
The stakes are extremely high for companies called before EU or US regulators and scientific experts to answer queries about their new drug applications at the later stages of the review process. How they perform is critical. Consultant Kate Dion has a raft of helpful tips for companies facing this daunting situation. Neena Brizmohun reports.
Topic Approvals
世界の薬事規制動向＆情報を配信
By Neena Brizmohun 06 Sep 2018
A new deal between Novartis and England’s National Health Service is one of the fastest funding approvals in the 70-year history of the NHS.
Topic Cancer
世界の薬事規制動向＆情報を配信
By Neena Brizmohun 08 Nov 2017
Novartis, having now submitted its CAR-T therapy CTL019 to the European Medicines Agency for approval.
Topic Drug Review
Medtech Insight: 世界の...
10 May 2016
世界の薬事規制動向＆情報を配信
07 Apr 2016
世界の薬事規制動向＆情報を配信
07 Apr 2016
Scrip: 世界の医療用医薬品＆製薬産...
06 Apr 2016
Medtech Insight: 世界の...
30 Mar 2016
Medtech Insight: 世界の...
29 Mar 2016
Medtech Insight: 世界の...
21 Mar 2016
世界の薬事規制動向＆情報を配信
18 Mar 2016
Medtech Insight: 世界の...
17 Mar 2016
Medtech Insight: 世界の...
17 Mar 2016
世界の薬事規制動向＆情報を配信
14 Mar 2016
世界の薬事規制動向＆情報を配信
11 Mar 2016
世界の薬事規制動向＆情報を配信
09 Mar 2016
Medtech Insight: 世界の...
07 Mar 2016
Scrip: 世界の医療用医薬品＆製薬産...
19 Feb 2016
